These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9098192)

  • 21. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
    Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
    PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
    J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of human glioma xenografts in vivo utilizing radiolabeled antibodies.
    Williams JA; Wessels BW; Wharam MD; Order SE; Wanek PM; Poggenburg JK; Klein JL
    Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1367-75. PubMed ID: 2370186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
    Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
    Domingo RJ; Reilly RM
    Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
    Pai-Scherf LH; Carrasquillo JA; Paik C; Gansow O; Whatley M; Pearson D; Webber K; Hamilton M; Allegra C; Brechbiel M; Willingham MC; Pastan I
    Clin Cancer Res; 2000 May; 6(5):1720-30. PubMed ID: 10815890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Radiother Oncol; 1997 Sep; 44(3):283-93. PubMed ID: 9380829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
    D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
    Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 90Y PET-based dosimetry after selective internal radiotherapy treatments.
    D'Arienzo M; Chiaramida P; Chiacchiararelli L; Coniglio A; Cianni R; Salvatori R; Ruzza A; Scopinaro F; Bagni O
    Nucl Med Commun; 2012 Jun; 33(6):633-40. PubMed ID: 22407156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis.
    Quadri SM; Malik AB; Chu HB; Freedman RS; Vriesendorp HM
    J Nucl Med; 1996 Sep; 37(9):1545-51. PubMed ID: 8790216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
    Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
    Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
    Fisher DR; Shen S; Meredith RF
    J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.